<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04780815</url>
  </required_header>
  <id_info>
    <org_study_id>NER 03/001</org_study_id>
    <nct_id>NCT04780815</nct_id>
  </id_info>
  <brief_title>A PET Study of Nicotine From myBlu E-cigarette Use</brief_title>
  <official_title>An Exploratory PET-study of Deposition, Disposition and Brain Uptake of [11C]Nicotine After Inhalation of 2 Nicotine Formulations Via the myBluTM E-cigarette in Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial Brands PLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nerudia Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial Brands PLC</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, exploratory PET-study of deposition, disposition and brain uptake&#xD;
      [11C]nicotine when given to smokers as two different formulations via mybluTM e-cigarette&#xD;
      system.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lung PET</measure>
    <time_frame>40 minutes</time_frame>
    <description>Amount of nicotine deposited in the lung during 40 minutes after product administration, using dynamic PET Digital Imaging and Communications in Medicine (DICOM) images over the lungs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral cavity PET</measure>
    <time_frame>40 minutes</time_frame>
    <description>Amount of nicotine deposited in the oral cavity during 40 minutes after product administration, using dynamic PET Digital Imaging and Communications in Medicine (DICOM) images over the oral cavity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain PET</measure>
    <time_frame>30 minutes</time_frame>
    <description>Amount of nicotine deposited in the brain during 30 minutes after product administration, using dynamic PET Digital Imaging and Communications in Medicine (DICOM) images over the brain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arterial blood radioactivity vs time profile</measure>
    <time_frame>2, 4, 6, 8, 10, 15, 20 and 30 minutes</time_frame>
    <description>Single-dose pharmacokinetics of 11C-labelled nicotine in arterial blood, by measuring radioactivity in arterial blood in discrete samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Day 1 to Day 7 (End of study)</time_frame>
    <description>Frequency, intensity and seriousness of adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>myBluTM Formulation 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>myBluTM Formulation 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>myBluTM Formulation 1</intervention_name>
    <description>1-2 puffs of each 3-5 seconds duration taken from myBluTM with Formulation 1, with inhalation of the vapour into the lungs</description>
    <arm_group_label>myBluTM Formulation 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>myBluTM Formulation 2</intervention_name>
    <description>1-2 puffs of each 3-5 seconds duration taken from myBluTM with Formulation 2, with inhalation of the vapour into the lungs</description>
    <arm_group_label>myBluTM Formulation 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index ≥18.0 and ≤ 30.0 kg/m2&#xD;
&#xD;
          -  Habitual daily cigarette smoker&#xD;
&#xD;
          -  Women have to be of non-child bearing potential&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of any clinically significant disease&#xD;
&#xD;
          -  Relevant concomitant medication&#xD;
&#xD;
          -  Any clinically significant condition&#xD;
&#xD;
          -  Malignancy within the past 5 years&#xD;
&#xD;
          -  Positif for HIV, hepatitis B or C&#xD;
&#xD;
          -  Untreated hypertension&#xD;
&#xD;
          -  Previous participation to a PET-study or other nuclide medical study&#xD;
&#xD;
          -  Previous exposure to significant radiation&#xD;
&#xD;
          -  Negative results of the modified Allen test on both arms at screening&#xD;
&#xD;
          -  Alcohol or drug abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>PET Centre, Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 23, 2021</study_first_submitted>
  <study_first_submitted_qc>March 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2021</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

